GLIS2 is a zinc finger transcription factor that functions as a context-dependent regulator of gene expression, acting as either a repressor or activator depending on cellular context. In normal kidney physiology, GLIS2 maintains epithelial differentiation by repressing SNAI1-mediated epithelial-to-mesenchymal transition and inhibits Wnt/β-catenin signaling, potentially through recruitment of corepressors CTBP1 and HDAC3 1. GLIS2 also negatively regulates Hedgehog signaling pathways 2. In polycystic kidney disease, GLIS2 emerges as a critical effector of polycystin-dependent cilia signaling required for cyst formation. Inactivation of Glis2 suppresses disease progression in ADPKD mouse models, and antisense oligonucleotide-mediated targeting of Glis2 slows disease development, positioning GLIS2 as a potential therapeutic target 1. Clinically, GLIS2 is highly relevant in pediatric leukemia when fused to CBFA2T3 or ETO2. These fusion proteins drive aggressive acute megakaryoblastic leukemia through aberrant transcriptional regulation of developmental pathways including NOTCH, Hedgehog, TGFβ, and WNT signaling 324. CBFA2T3-GLIS2 fusions characterize a pediatric-specific AML subtype with extremely poor prognosis (15-30% overall survival) 5. Fusion-driven leukemias show sensitivity to BCL2 inhibition and combined MEK/BCL2 inhibition strategies 34.